Lone Star Bio

Found 17,151 articles

• Advanced Infusion Care (AIC) now offers Eisai infusion therapy LEQEMBI™ (Lecanemab-irmb) humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody

  5/23/2023

  Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer’s disease.

• Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System

  5/23/2023

  Genprex, Inc. today released a new video where the company's Chief Medical Officer, Mark Berger, MD, discusses the recently presented positive preclinical data for the NPRL2 gene by Genprex's research collaborators.

• Monogram Orthopaedics Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

  5/23/2023

  Monogram Orthopaedics Inc. announced it has engaged international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets.

• Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Extensive Research at ASCO 2023

  5/23/2023

  Caris Life Sciences® announced that the company and collaborators within the Caris Precision Oncology Alliance™ will collectively present 42 studies across more than 30 solid tumor types at the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6, 2023.

• Atrion Corporation Declares Quarterly Cash Dividend - May 23, 2023

  5/23/2023

  Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock.

• TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

  5/23/2023

  TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) today announced that CEO Harlan Weisman, M.D. will be presenting a corporate overview at the 2023 Jefferies Healthcare Conference being held in-person in New York, NY on June 7-9, 2023.

• Baylor Genetics Announces Neuromuscular Disorders Panel

  5/22/2023

  Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, announced the availability of a Neuromuscular Disorders Panel.

• Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

  5/22/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh.

• Lumos Pharma to Participate in World Orphan Drug Congress USA

  5/22/2023

  Lumos Pharma, Inc., a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency through Phase 2 clinical trials, announced that management will participate in panel discussions at the World Orphan Drug Congress USA 2023, held in Washington, D.C., May 23-25, 2023.

• bioAffinity Technologies Presents Research Findings at CYTO 2023

  5/22/2023

  bioAffinity Technologies, Inc. today will present the poster “Development of porphyrin-stained polystyrene compensation beads for use on an automated analysis platform” at CYTO 2023 , the annual Congress for the International Society for the Advancement of Cytometry (ISAC), in Montréal, Québec, Canada.

• FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsXBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment

  5/22/2023

  XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis.

• 7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

  5/22/2023

  7 Hills Pharma LLC announced that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas to advance 7HP349, its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.

• Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023

  5/22/2023

  Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE).

• Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress

  5/22/2023

  Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in multiple presentations at the World Orphan Drug Congress, taking place May 23-25, 2023.

• Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - May 19, 2023

  5/19/2023

  Forte Biosciences, Inc., a biopharmaceutical company focused on autoimmune diseases, announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

• Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

  5/19/2023

  Taysha Gene Therapies today presents preclinical data from neonatal mouse models on TSHA-102 for Rett syndrome, including new data in wild-type mice, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

• Monogram Orthopaedics Shares Begin Trading Publicly on NASDAQ

  5/18/2023

  Monogram Orthopedics announced it raised $17,216,147 is pleased to announce that its common stock will begin trading on the NASDAQ, May 18, 2023, at approximately 11:00 am EST under the ticker symbol "MGRM."

• Colossal Biosciences and the Vertebrate Genomes Project Publish the First Near Complete African Elephant Chromosome Level Genome

  5/18/2023

  Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project, which aims to sequence high-quality reference genomes for all living vertebrates, partnered to successfully generate the first high-quality reference genome of the African elephant.

• Paradromics Raises $33 Million in Funding, Achieves Breakthrough Medical Device Designation from FDA

  5/18/2023

  Paradromics Inc., the leading developer of high data-rate brain-computer interfaces (BCI), today announced a $33 million Series A funding round led by Prime Movers Lab.

• Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

  5/18/2023

  Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, May 25, 2023.